

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal

#### Sotatercept for treating pulmonary arterial hypertension ID6163

#### Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Merck Sharp &amp; Dohme (sotatercept)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Blood Pressure UK</li> <li>• British Cardiovascular Society</li> <li>• Asthma and Lung UK</li> <li>• Cardiovascular Care Partnership</li> <li>• Circulation Foundation</li> <li>• Heart UK</li> <li>• Network of Sikh Organisations</li> <li>• Pulmonary Hypertension Association UK</li> <li>• Pumping Marvellous Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• British and Irish Hypertension Society</li> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Haematology</li> <li>• British Society for Heart Failure</li> <li>• British Society of Cardiovascular Imaging</li> <li>• British Thoracic Society</li> <li>• National Heart and Lung Institute</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• ADVANZ Pharma (warfarin, furosemide, nifedipine, nicardipine, epoprostenol)</li> <li>• Aguetant (nicardipine)</li> <li>• AmaroX (amlodipine, sildenafil)</li> <li>• AS Kalceks (furosemide)</li> <li>• Aspire Pharma (tadalafil)</li> <li>• Aurobindo Pharma (amlodipine, bosentan, sildenafil, tadalafil)</li> <li>• Baxter Healthcare (furosemide)</li> <li>• Bayer (nifedipine)</li> <li>• Brillpharma (amlodipine)</li> <li>• Chiesi (nifedipine)</li> <li>• Cipla EU (ambrisentan, bosentan, tadalafil)</li> <li>• Crescent Pharma (sildenafil)</li> </ul>

Provisional stakeholder list for the evaluation of sotatercept for treating pulmonary arterial hypertension ID6163

Issue date: July 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society for Vascular Nurses</li> <li>• Society for Vascular Technology</li> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Dexcel Pharma (nifedipine)</li> <li>• Dr. Reddy's Laboratories (amlodipine, ambrisentan, bosentan, sildenafil)</li> <li>• Eli Lilly and Company (tadalafil)</li> <li>• Ethypharm UK (diltiazem)</li> <li>• FDC International (amlodipine)</li> <li>• Galen (diltiazem)</li> <li>• Genus Pharmaceuticals (nifedipine)</li> <li>• GlaxoSmithKline (ambrisentan, epoprostenol)</li> <li>• Hameln Pharma (furosemide)</li> <li>• Ipca Laboratories UK (furosemide, amlodipine)</li> <li>• Janssen-Cilag (macitentan, epoprostenol, selexipag)</li> <li>• Merck Sharp &amp; Dohme (riociguat)</li> <li>• Morningside Healthcare (nifedipine)</li> <li>• Mylan (bumetanide, amlodipine, ambrisentan, bosentan, sildenafil, tadalafil)</li> <li>• Napp Pharmaceuticals (diltiazem)</li> <li>• Pinewood Healthcare (furosemide)</li> <li>• Ranbaxy (warfarin, tadalafil, epoprostenol)</li> <li>• Renascience Pharma (metolazone)</li> <li>• Rosemont Pharmaceutical (warfarin, furosemide, bumetanide, amlodipine, sildenafil)</li> <li>• Sandoz (amlodipine, sildenafil)</li> <li>• Sanofi (diltiazem, tadalafil)</li> <li>• Sigma Pharmaceuticals (sildenafil)</li> <li>• Sovereign Medical (tadalafil)</li> <li>• Strides Pharma UK (warfarin)</li> <li>• Teva Pharma (sildenafil)</li> <li>• Thame Laboratories (furosemide, amlodipine)</li> <li>• The Boots Company (sildenafil)</li> <li>• Thornton &amp; Ross (nifedipine, diltiazem)</li> <li>• Tillomed Laboratories (nifedipine)</li> <li>• UCB Pharma (nifedipine)</li> <li>• Upjohn UK (amlodipine, sildenafil)</li> <li>• Zentiva (diltiazem, amlodipine, ambrisentan)</li> </ul> <p><u>Relevant research groups</u></p>

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research</li> <li>• Cardiac and Cardiology Research Dept, Barts</li> <li>• Circulation Foundation</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Hypertension Group</li> <li>• Cochrane UK</li> <li>• Cochrane Vascular</li> <li>• European Council for Cardiovascular Research</li> <li>• Genomics England</li> <li>• Heart Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Health Research</li> <li>• Wellcome Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.